Given the dual role of CXCR4 in HIV pathogenesis and cancer biology, the therapeutic application of CXCR4 antagonists in HIV-positive breast cancer patients may have a potentially synergistic effect: slowing down the progression of HIV while simultaneously impeding tumor proliferation, chemotaxis and metastatic dissemination of breast cancer. This evidence concerns the gene CXCR4 and breast carcinoma.